ISSN 1662-4009 (online)

ey0021.10-14 | New Biomarkers | ESPEYB21

10.14. RANKL/RANK is required for cytokine-induced beta cell death; osteoprotegerin, a RANKL inhibitor, reverses rodent type 1 diabetes

NG Kondegowda , J Filipowska , JS Do , N Leon-Rivera , R Li , R Hampton , al. et

Brief Summary: Through a series of experiments in the nonobese diabetic/Ltj mouse model and human β-cells, the authors show that the RANK pathway mediates cytokine-induced β-cell death through RANK-TRAF6 interaction and induction of NF-KB activation. Inhibition of the RANKL/RANK pathway following treatment with osteoprotegerin and denosumab protected β-cells against this cytotoxicity, reduced proinflammatory cytokines in activated T-cells, and reversed T1D in th...